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Background: Glutathione peroxidase 3 (GPx3) which is
an extracellular secretory protein is down regulated in
patients with early stage lung cancer. We examined the
usefulness of serum GPx3 as a biomarker for monitoring
of relapse after surgery.
Methods: We prospectively collected serial serum
samples at baseline, 3 months (3m), 6 months (6m), and
12 months (12m) after operation from the patients who
underwent surgery during the year 2013. GPx3 levels
were measured three times per sample using the
enzyme-linked immunosorbent assay, and the mean
values were analyzed by t-test and paired t-test.
Results: A total of 170 (100 adenocarcinoma, 41
squamous cell carcinoma, 29 others) patients were
analyzed in this study. Mean age was 64.1 years old
(range, 39-80) and 27 (15.9%) out of 165 lung cancer
patients were conﬁrmed relapse during the median
follow-up period of 597.5 days (range, 5-938). The
mean GPx3 value at postoperative 6m was signiﬁcantly
elevated in relapsed group than control group (7.90 ±
2.44 mg/mL vs. 6.99 ± 1.79 mg/mL, p¼0.047). The mean
GPx3 differences were signiﬁcantly higher in relapsed
group than control group at 3m (-0.38 ± 0.39 mg/mL vs.
-0.21 ± 0.36 mg/mL, p¼0.044), 6m (-0.37 ± 0.42 mg/mL
vs. -0.19 ± 0.30 mg/mL, p¼0.024), and 12m (-0.38 ±
0.42 mg/mL vs. -0.19 ± 0.28 mg/mL, p¼0.012). The
mean time to relapse was signiﬁcantly shorter in high
level of GPx3 group at postoperative 3m (694.83 ±
31.86 days vs. 839.05 ± 24.31 days, p¼0.007). The
mean time to relapse was signiﬁcantly shorter in high
GPx3 difference group between baseline and post-
operative 3m (729.76 ± 34.89 days vs. 838.18 ± 24.03
days, p¼0.002).
Conclusion: Serum mean GPx3 value at postoperative
6m and the mean GPx3 difference were signiﬁcantly
elevated in relapsed lung cancer. The mean time to
relapse was signiﬁcantly shorter in high level of GPx3
group at postoperative 3m. More large scaled validation
studies are warranted.* Due to unforeseen circumstance, this poster was not presented.The biological impact of e-cigarettes
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Because the electronic cigarette (ECIG) is designed to
deliver nicotine without combusting tobacco, they are
widely advertised as a safer alternative to tobacco cigarettes
(TCIGs). ECIGs are controversial due to the lack of quality
control standards and the paucity of data on their safety and
long–term health effects. The absence of product standards
and regulation, leading to variability in product quality is a
major concern. Studies analyzing the contents of the ECIG
cartridge and/or vapor have revealed the presence of major
tobacco-speciﬁc nitrosamines, volatile organic compounds,
and metals. Multiple studies have detected inconsistent
levels of nicotine in cartridges and reﬁlls between ECIG
manufacturers compared to the content labeling. For this
reason, each component of ECIGs is the subject of public
health and safety concern. In this study, we assess the
impact of ECIG exposure on the carcinogenic potential of
immortalized human bronchial epithelial cells on a back-
ground of silenced p53 and activated KRAS, mutations often
observed in the airway of current and former smokers at
risk for lung cancer. Our preliminary results demonstrate
that exposure to clinically relevant concentrations of ECIG
vapor-conditioned media enhance the cancer-associated
behavior of ‘at-risk’ airways with a demonstrated capacity
for malignant transformation. We observed enhanced col-
ony growth in anchorage independent assays and increased
cell invasion-associated morphological changes in three-
dimensional air-liquid interface models. In addition, we
found that mutant epithelial cells exposed to ECIG vapor-
conditionedmedia induces airway gene expression changes
that are similar to those seenwith TCIG exposure. Currently,
we are deﬁning an ECIG exposure signature. In addition, we
will also evaluate the effects of chemical substances present
in ECIGs such as tobacco-speciﬁc nitrosamines. These
studies will identify the potential impact of ECIGs on airway
epithelium carcinogenesis and add to our overall under-
standing of early disease pathogenesis in human lung can-
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